Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Adenosine Deaminase-Severe Combined Immunodeficiency Market Forecast: What Market Value Is Expected By 2030?

In the realm of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID) treatment, the market has experienced robust expansion lately. Projections indicate a continued upward trajectory, with the market value set to increase from $5.94 billion in 2025 to $6.33 billion in 2026, reflecting a compound annual growth rate of 6.6%. Historically, several factors have underpinned this market’s growth, including a limited understanding of ADA-SCID, the scarce availability of gene therapy as a treatment option, a prevailing dependence on supportive care measures, a deficit in dedicated treatment facilities, and the significant issue of delayed diagnoses and treatment initiation.

The market for adenosine deaminase-severe combined immunodeficiency is poised for considerable expansion, projected to reach $8.11 billion by 2030, reflecting a compound annual growth rate of 6.4%. This anticipated growth throughout the forecast period is propelled by several key factors, including the progression of autologous stem cell therapies, enhanced accessibility to enzyme replacement therapies, an increase in dedicated specialized hospitals and clinics, a rise in the diagnosis of pediatric cases, and augmented healthcare funding specifically allocated for rare genetic disorders. Furthermore, significant trends shaping this market’s future encompass the growing utilization of enzyme replacement therapies, the accelerating development and availability of gene therapy options, a surge in stem cell transplantation procedures, broader implementation of pediatric treatment programs for ADA-SCID, and a heightened emphasis on providing comprehensive supportive care alongside diligent patient monitoring.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21085&type=smp

Adenosine Deaminase-Severe Combined Immunodeficiency Market Development Factors: Which Trends Are Supporting Demand?

The increasing incidence of genetic conditions is anticipated to be a significant catalyst for the expansion of the adenosine deaminase-severe combined immunodeficiency market. Genetic disorders, characterized by alterations or defects in an individual’s genetic makeup, can be passed down through generations or arise spontaneously, and their growing prevalence is attributed to advancements in diagnostic tools, heightened public awareness, later age of parenthood, environmental factors, and an expanding global population. This surge in genetic disorders, including specific conditions like adenosine deaminase-severe combined immunodeficiency (ADA-SCID), consequently fuels a greater need for sophisticated diagnostic approaches and specialized therapeutic interventions. As an illustration, the Cystic Fibrosis Trust, a prominent UK charity, reported that the number of individuals diagnosed with cystic fibrosis (CF) in the United Kingdom rose from 11,148 in 2022 to 11,318 in 2023, underscoring the trend. Consequently, the escalating occurrence of genetic disorders is a primary driver behind the growth trajectory of the adenosine deaminase-severe combined immunodeficiency market.

Adenosine Deaminase-Severe Combined Immunodeficiency Market Segmentation: How Is The Market Structured Across Key Categories?

The adenosine deaminase-severe combined immunodeficiency market covered in this report is segmented –

1) By Treatment Type: Enzyme Replacement Therapy (ERT), Gene Therapy, Stem Cell Transplantation, Supportive Care Treatments

2) By Route of Administration: Intravenous, Subcutaneous

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Enzyme Replacement Therapy (ERT): Pegylated Adenosine Deaminase, Non-Pegylated Adenosine Deaminase

2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy, Viral Vector-Mediated Gene Therapy

3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant, Umbilical Cord Blood Transplant

4) By Supportive Care Treatments: Antimicrobial Therapy, Immune System Support

Adenosine Deaminase-Severe Combined Immunodeficiency Market Transformation Trends: Which Innovations Are Driving Change?

Leading entities within the adenosine deaminase-severe combined immunodeficiency (ADA-SCID) treatment sector are prioritizing the advancement of innovative approaches, including the establishment of domestic gene therapy manufacturing capabilities. This strategic shift aims to enhance patient accessibility to treatments, lower associated expenditures, and guarantee an uninterrupted supply chain for these crucial therapies. The concept of in-house gene therapy production entails a company’s internal manufacturing of genetically modified autologous hematopoietic stem cells, which are engineered to carry a functional ADA gene, thereby lessening reliance on external commercial producers. Illustrating this trend, the Fondazione Telethon, a research-focused non-profit organization based in Italy, put forth a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in February 2025. This application was for etuvetidigene autotemcel, a gene therapy initially conceived for ADA-SCID that is now also being explored for Wiskott-Aldrich Syndrome. This therapeutic intervention involves a singular administration of the patient’s own CD34+ stem and progenitor cells, which have been genetically altered using a lentiviral vector to incorporate the functional gene, demonstrating encouraging results regarding both safety and therapeutic effectiveness in individuals receiving the treatment.

Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Landscape And Leading Companies

Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are GlaxoSmithKline plc, Chiesi Farmaceutici S.p.A., Orchard Therapeutics PLC, Rocket Pharmaceuticals, Novartis AG, Bluebird Bio, Spark Therapeutics, Leadiant Biosciences, Sigma-Tau Pharmaceuticals, Astellas Pharma, Takeda Pharmaceutical Company, Pfizer Inc, Sanofi, Bristol-Myers Squibb, Roche Holding AG, Johnson & Johnson, AbbVie Inc, Gilead Sciences, CSL Limited, Bayer AG

Access The Complete Adenosine Deaminase-Severe Combined Immunodeficiency Market Report:

https://www.thebusinessresearchcompany.com/report/adenosine-deaminase-severe-combined-immunodeficiency-global-market-report

Adenosine Deaminase-Severe Combined Immunodeficiency Market Regional Analysis And Leading Geography

North Americawas the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2025. The regions covered in the adenosine deaminase-severe combined immunodeficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model